Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Central nervous system toxicity with fludarabine.

D E Merkel, N L Griffin, K Kagan-Hallet

    Cancer Treatment Reports
    |December 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
    Same author

    The upper limb of Paranthropus boisei from Ileret, Kenya.

    Journal of human evolution·2020
    Same author

    Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

    Cancer chemotherapy and pharmacology·2014

    Fludarabine can cause serious delayed neurotoxicity, including encephalopathy and blindness, even at low doses. This neurological vulnerability is unpredictable, necessitating caution with this antineoplastic agent.

    Area of Science:

    • Neuroscience
    • Oncology
    • Pharmacology

    Background:

    • Fludarabine is an antineoplastic agent used in cancer treatment.
    • Delayed neurotoxicity, including encephalopathy and cortical blindness, has been associated with fludarabine therapy.
    • Previously, this toxicity was primarily reported in patients receiving high, aplasia-inducing doses.

    Observation:

    • This report details two patients experiencing subacute neurological deterioration.
    • One of these patients had received only low doses of fludarabine.
    • The observed cases suggest a broader susceptibility to fludarabine-induced neurotoxicity.

    Findings:

    • Fludarabine can induce serious delayed neurotoxicity, manifesting as encephalopathy and cortical blindness.
    • Neurotoxicity may occur even with low-dose fludarabine administration.

    Related Experiment Videos

  • The neurological vulnerability to fludarabine appears multifactorial and currently unpredictable.

    • Implications:

    • Low-dose fludarabine may pose a risk for neurological adverse events.
    • Clinical vigilance is required when administering fludarabine, regardless of dose.
    • Further research is needed to understand and predict neurotoxicity risk associated with fludarabine.